Osamu Shimozato
Overview
Explore the profile of Osamu Shimozato including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
503
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hoshi D, Kita E, Maru Y, Kogashi H, Nakamura Y, Tatsumi Y, et al.
Cancer Sci
. 2022 Nov;
114(3):1165-1179.
PMID: 36382538
Acinar cell carcinoma (ACC) of the pancreas is a malignant tumor of the exocrine cell lineage with a poor prognosis. Due to its rare incidence and technical difficulties, few authentic...
2.
Iwatate Y, Yokota H, Hoshino I, Ishige F, Kuwayama N, Itami M, et al.
PLoS One
. 2022 Jun;
17(6):e0268630.
PMID: 35648752
Transcriptomic analysis of cancer samples helps identify the mechanism and molecular markers of cancer. However, transcriptomic analyses of pancreatic cancer from the Japanese population are lacking. Hence, in this study,...
3.
Iwatate Y, Yokota H, Hoshino I, Ishige F, Kuwayama N, Itami M, et al.
Int J Oncol
. 2022 Apr;
60(5).
PMID: 35419611
Radiogenomics has attracted attention for predicting the molecular biological characteristics of tumors from clinical images, which are originally a collection of numerical values, such as computed tomography (CT) scans. A...
4.
Kinoshita H, Shimozato O, Ishii T, Kamoda H, Hagiwara Y, Ohtori S, et al.
Anticancer Res
. 2021 Dec;
41(12):6013-6021.
PMID: 34848455
Background/aim: The thioredoxin-1 (Trx-1) inhibitor, PX-12, is active against several cancer types. This study aimed to evaluate its effects on local osteosarcoma (OS) progression and to describe PX-12-related signal transduction...
5.
Hoshino I, Yokota H, Iwatate Y, Mori Y, Kuwayama N, Ishige F, et al.
Cancer Sci
. 2021 Oct;
113(1):229-239.
PMID: 34689378
Tumor mutational burden (TMB) is gaining attention as a biomarker for responses to immune checkpoint inhibitors in cancer patients. In this study, we evaluated the status of TMB in primary...
6.
Kinoshita H, Shimozato O, Ishii T, Kamoda H, Hagiwara Y, Tsukanishi T, et al.
Anticancer Res
. 2021 Oct;
41(10):4947-4955.
PMID: 34593442
Background/aim: Auranofin (AUR), a thioredoxin reductase (TXNRD) inhibitor, shows anticancer activity against several cancers. This study investigated the effects of AUR on the local progression and pulmonary metastasis of osteosarcoma...
7.
Mori Y, Takeuchi A, Miyagawa K, Yoda H, Soda H, Nabeya Y, et al.
FEBS Open Bio
. 2021 Mar;
11(5):1382-1394.
PMID: 33720534
During the early phase of tumorigenesis, primary malignant cells survive within a low nutrition environment caused by a poorly organized vascular system. Here, we sought to determine the functional significance...
8.
Matsushita M, Mori Y, Uchiumi K, Ogata T, Nakamura M, Yoda H, et al.
FEBS Open Bio
. 2019 Apr;
9(5):935-946.
PMID: 30947381
Receptor-type protein tyrosine phosphatase κ (PTPRK) is considered to be a candidate tumor suppressor. PTPRK dephosphorylates CD133, which is a stem cell marker; phosphorylated CD133 accelerates xenograft tumor growth of...
9.
Sun D, Yu M, Li Y, Xing H, Gao Y, Huang Z, et al.
FEBS Open Bio
. 2019 Mar;
9(3):478-489.
PMID: 30868056
Tumor suppressor p53 is a short-lived nuclear transcription factor, which becomes stabilized and activated in response to a wide variety of cellular stresses. Around 50% of human cancer tissues carry...
10.
Inoue T, Shimozato O, Matsuo N, Mori Y, Shinozaki Y, Lin J, et al.
Bioorg Med Chem
. 2018 Apr;
26(9):2337-2344.
PMID: 29622411
To examine the hydrophobic structure of PI polyamides on tumor accumulation in vivo, PI polyamide-fluorescein conjugates 1-5 with the distinct number of N-methylimidazole (Im) units were synthesized. There existed an...